Compositions and methods for the treatment of carboxyhemoglobinemia
View Patent ↗Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
1. A method of treating carboxyhemoglobinemia in a subject, comprising:
selecting a subject with carboxyhemoglobinemia; and
administering to the subject a therapeutically effective amount of a human recombinant neuroglobin, comprising:
a H64Q, H64A, or H64W mutation, and
a C46G mutation, a C55S mutation, a C120S mutation, or any combination thereof.
2. The method of claim 1 , wherein the human recombinant neuroglobin comprises the amino acid sequence of SEQ ID NO: 3.
3. The method of claim 1 , wherein the human recombinant neuroglobin has a solubility that is superior to the solubility of wild type neuroglobin.
4. The method of claim 1 , wherein the human recombinant neuroglobin is in monomeric form.
5. The method of claim 1 , wherein the subject has at least 3%, at least 5%, at least 10%, at least 15% or at least 20% carboxyhemoglobin in their blood.
6. The method of claim 1 , wherein the human recombinant neuroglobin molecule is administered by intravenous infusion.
7. The method of claim 1 , wherein the therapeutically effective amount of the human recombinant neuroglobin molecule is about 50 to about 800 grams.
8. A method of treating carboxyhemoglobinemia in a subject, comprising:
selecting a subject with carboxyhemoglobinemia; and
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
a human recombinant neuroglobin comprising:
a H64Q, H64A or H64W mutation; and
a C46G mutation, a C55S mutation, a C120S mutation, or any combination thereof; and
a pharmaceutically acceptable carrier.
9. The method of claim 8 , wherein the human recombinant neuroglobin comprises the amino acid sequence of SEQ ID NO: 3.
10. The method of claim 8 , wherein the human recombinant neuroglobin has a solubility that is superior to the solubility of wild type neuroglobin.
11. The method of claim 8 , wherein the human recombinant neuroglobin is in monomeric form.
12. The method of claim 8 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a wetting agent, an emulsifying agent, a preservative, and a pH buffering agent.
13. The method of claim 8 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of sodium acetate or sorbitan monolaurate.
14. The method of claim 8 , wherein the subject has at least 3%, at least 5%, at least 10%, at least 15% or at least 20% carboxyhemoglobin in their blood.
15. The method of claim 8 , wherein the pharmaceutical composition is administered by intravenous infusion.
16. The method of claim 8 , wherein the pharmaceutical compositions comprises about 50 to about 800 grams of the human recombinant globin molecule.